Basilea secures $30 million BARDA funding to advance Phase 3 development of its antifungal fosmanogepix
Executive summary: Basilea received a $30 million funding award from BARDA to advance Phase 3 development of its antifungal fosmanogepix. The award provides non‑dilutive capital for costly Phase 3 trials and supports the development of a needed antifungal amid rising resistant infections.
Who is involved: Basilea Pharmaceuticals; Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services.
Likely next: Basilea will use the funds to progress fosmanogepix through Phase 3 trials, with potential regulatory milestones and additional BARDA payments contingent on trial progress.
Basilea announced that it has received a $30 million tranche under its existing agreement with the Biomedical Advanced Research and Development Authority (BARDA). The funds are earmarked for moving the novel antifungal agent fosmanogepix into Phase 3 clinical trials, addressing a growing need for new treatments against drug‑resistant fungal infections. This non‑dilutive financing reduces Basilea’s R&D cash‑burn and signals continued U.S. government support for antimicrobial countermeasure development.
Timeline
- — Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix (GlobeNewswire)
- — Sapphiros Secures $12.4 Million BARDA Award to Advance Rapid Molecular Diagnostics for Biothreat Detection (PR Newswire)
Analysis — what this means
Sectors affected
- systemic antifungal therapy
Historical parallels
- Sapphiros received $12.4 million BARDA award on 14 July 2026 for rapid molecular diagnostics
Key entities
Sources
- Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix — GlobeNewswire
- Sapphiros Secures $12.4 Million BARDA Award to Advance Rapid Molecular Diagnostics for Biothreat Detection — PR Newswire